Health Catalyst Q4 revenue $79.6M (+6% YoY); raises 2025 Adjusted EBITDA target to $41M

Health Catalyst, Inc.

2024-FY EPS reported -$1.15 revenue$306,584,000

Q4 revenue $79.6M (+6% YoY); full-year revenue $306.6M (+4% YoY).
Net loss improved to $20.7M in Q4 ($30.3M prior year); full-year net loss $69.5M vs $118.1M.
Technology segment Q4 revenue $52M (+10% YoY); full-year Tech revenue $195M.
2025 Adjusted EBITDA target raised to approximately $41M, up $2M from prior outlook.
Director Anita Pramoda resigns effective March 1; Dr. Jill Hoggard Green joined Board Dec 1. Also promotions: Chief AI Officer and leadership team appointments.

item 2.02 item 9.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Anita Pramoda

Director

HCAT · Health Catalyst, Inc.

Effective: 2025-03-01
Filed: February 26, 2025, 6:59 PM ET

On February 20, 2025, Anita Pramoda informed the Board of her resignation from the Board, and on February 20, 2025, the Board accepted her resignation, including her resignation from the compensation committee and transactions committee of the Board, effective March 1, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anita Pramoda resigned as Director at Health Catalyst, Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 20, 2025, Anita Pramoda informed the Board of her resignation from the Board, and on February 20, 2025, the Board accepted her resignation, including her resignation from the compensation committee and transactions committee of the Board, effective March 1, 2025.

View on SEC.gov

Health Catalyst, Inc. filing history →

Source: SEC EDGAR

accession 0001636422-25-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.